IGBA Launches A Biosimilar Medicines Information Campaign

Thursday February 1, 2018

Contact: David Gaugh [email protected]

Today, the International Generic and Biosimilar medicines Association (IGBA) launched an information campaign on biosimilar medicines. The foundation of this campaign is the IGBA biosimilar medicines public slide deck[1]. Access to well-referenced information is fundamental to improving worldwide understanding and acceptance of biosimilar medicines, which support patient access to life-saving treatments, enhance competition and contribute to healthcare system sustainability by offering savings for the same medical outcome.

Biosimilar medicines, like their reference medicinal products, help treat many complex diseases, including cancers, rheumatoid arthritis, psoriasis, inflammatory bowel disease, growth disorders and diabetes.

The EU has approved the highest number of biosimilar medicines worldwide, and has acquired considerable experience of their use and safety. There is real world experience available of over 700 Million patient days from EU licensed biosimilar medicines alone[2], and “over the last 10 years, the EU monitoring system for safety concerns has not identified any difference in the nature, severity or frequency of adverse effects between biosimilars and their reference medicine[3]. IGBA believes that this accumulated wealth of clinical experience with biosimilar medicines can become a worldwide game-changer for access to medicines for certain complex medical conditions.

The slide deck has been developed to be shared for educational purposes with any stakeholder, and is complementary to the extensive information on biosimilar medicines, which has already been made available for example in the USA[4] and the European Union[5].

About IGBA

The International Generic and Biosimilar Medicines Association (IGBA) was founded as IGPA (International Generic Pharmaceutical Alliance) in March 1997 to strengthen cooperation between associations representing manufacturers of generic medicines from around the world. Its membership includes AAM (USA), CGPA (Canada), GBM – Southern Africa (South Africa), IPA (India), JAPM (Jordan), JGA (Japan), Medicines for Europe (Europe), and TGPA (Taiwan), while the associations from Australia (GBMA), Brazil (ProGenericos), Mexico (AMEGI), and Malaysia (MOPI) are Associate Members. The IGBA is at the forefront of preserving sustainable competition within our industry, by stimulating competitiveness and innovation in the pharmaceutical sector; thereby, ensuring millions of patients around the world have access to high quality, pro-competitive medicines. Through its constituent member associations, the IGBA maintains constant dialogue with government authorities around the world, as well as with international institutions such as WTO, WIPO and WHO. More information: www.igbamedicines.org

[1] IGBA Communication on biosimilar medicines

[2] Biosimilar Medicines Clinical Use: An Experience Based-EU Perspective

[3] EMA – European Commission: Biosimilars in the EU – Information guide for healthcare professionals, 2017 (link)

[4] U.S. FDA Patient and Prescribers Outreach Materials on Biosimilars

[5] What I need to know about Biosimilar Medicines – Information for patients

Please see the official release here

View the IGBA resources here

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.

  • This field is for validation purposes and should be left unchanged.

Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more

GRx+Biosims 2019

Join us in Bethesda, Maryland on November 4-6, 2019 for the premier scientific and regulatory event for the U.S. generics and biosimilars industries.

LEARN MORE

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.

SIGN UP FOR OUR NEWSLETTER